Shay Shemesh - Feb 8, 2022 Form 3 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role
Chief Development Officer
Signature
/s/ Shay Shemesh
Stock symbol
NVCT
Transactions as of
Feb 8, 2022
Transactions value $
$0
Form type
3
Date filed
2/8/2022, 07:37 AM
Previous filing
Feb 8, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NVCT Common Stock 1.18M Feb 8, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 48,399 shares of restricted stock issued pursuant to Mr. Shemesh's employment arrangement upon the consummation of a $15.3 million private equity financing. This restricted stock award (RSA) vests on July 27, 2022, one year after the grant date.